{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T04:35:05Z","timestamp":1792211705640,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["SA359U14"],"award-info":[{"award-number":["SA359U14"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["IPT-2012-0779-010000"],"award-info":[{"award-number":["IPT-2012-0779-010000"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["DT15S\/00166"],"award-info":[{"award-number":["DT15S\/00166"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI14\/01776"],"award-info":[{"award-number":["PI14\/01776"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/01055"],"award-info":[{"award-number":["PI15\/01055"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD016\/0009\/0025"],"award-info":[{"award-number":["RD016\/0009\/0025"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI17\/01979"],"award-info":[{"award-number":["PI17\/01979"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004895","name":"European Social Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.biopha.2019.109684","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T17:29:22Z","timestamp":1574702962000},"page":"109684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"special_numbering":"C","title":["Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations"],"prefix":"10.1016","volume":"121","author":[{"given":"Alfredo G.","family":"Casanova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vicente-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Hern\u00e1ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Rihuete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura M.","family":"Ramis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"del Barco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Cruz-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Mart\u00ednez-Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mois\u00e9s","family":"Pescador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana I.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (1)","key":"10.1016\/j.biopha.2019.109684_bib0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R\u2019s of drug induced nephrotoxicity","volume":"18","author":"Awdishu","year":"2017","journal-title":"BMC Nephrol."},{"issue":"June (12)","key":"10.1016\/j.biopha.2019.109684_bib0010","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/ki.2010.475","article-title":"Drug use and nephrotoxicity in the intensive care unit","volume":"81","author":"Perazella","year":"2012","journal-title":"Kidney Int."},{"issue":"December (12)","key":"10.1016\/j.biopha.2019.109684_bib0015","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1517\/17425255.2014.967681","article-title":"Cell- and biomarker-based assays for predicting nephrotoxicity","volume":"10","author":"Huang","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"April (2)","key":"10.1016\/j.biopha.2019.109684_bib0020","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ccc.2006.02.003","article-title":"Drug-associated renal dysfunction","volume":"22","author":"Taber","year":"2006","journal-title":"Crit. Care Clin."},{"issue":"August (2)","key":"10.1016\/j.biopha.2019.109684_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/ki.2015.115","article-title":"Phenotype standardization for drug-induced kidney disease","volume":"88","author":"Mehta","year":"2015","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.biopha.2019.109684_bib0030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00467-016-3394-5","article-title":"Tubulointerstitial nephritis: diagnosis, treatment, and monitoring","volume":"32","author":"Joyce","year":"2017","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.biopha.2019.109684_bib0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1159\/000445467","article-title":"Clinical scenarios in acute kidney injury-parenchymal acute kidney injury - vascular diseases","volume":"188","author":"Meola","year":"2016","journal-title":"Contrib. Nephrol."},{"issue":"May (4)","key":"10.1016\/j.biopha.2019.109684_bib0040","first-page":"110","article-title":"Acute tubular necrosis: an old term in search for a new meaning within the evolving concept of acute kidney injury","volume":"2","author":"Sancho-Mart\u00ednez","year":"2015","journal-title":"New Horiz. Transl. Med."},{"issue":"July (7)","key":"10.1016\/j.biopha.2019.109684_bib0045","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfu016","article-title":"The economic impact of acute kidney injury in England","volume":"29","author":"Kerr","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"November (11)","key":"10.1016\/j.biopha.2019.109684_bib0050","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1681\/ASN.2004090740","article-title":"Acute kidney injury, mortality, length of stay, and costs in hospitalized patients","volume":"16","author":"Chertow","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl 2","key":"10.1016\/j.biopha.2019.109684_bib0055","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1179\/acb.2007.077","article-title":"Acute kidney injury, length of stay, and costs in patients hospitalized in the intensive care unit","volume":"62","author":"Vandijck","year":"2007","journal-title":"Acta Clin. Belg."},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.109684_bib0060","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","author":"Thomas","year":"2015","journal-title":"Kidney Int."},{"issue":"November (5)","key":"10.1016\/j.biopha.2019.109684_bib0065","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00280-015-2880-y","article-title":"Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients","volume":"76","author":"Shinke","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"April (4)","key":"10.1016\/j.biopha.2019.109684_bib0070","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/ncpneph0746","article-title":"Defining acute kidney injury: what is the most appropriate metric?","volume":"4","author":"Solomon","year":"2008","journal-title":"Nat. Clin. Pract. Nephrol."},{"issue":"July","key":"10.1016\/j.biopha.2019.109684_bib0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/s13054-016-1373-7","article-title":"Acute kidney injury: from clinical to molecular diagnosis","volume":"20","author":"Ronco","year":"2016","journal-title":"Crit. Care"},{"issue":"June (3)","key":"10.1016\/j.biopha.2019.109684_bib0080","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1186\/cc11240","article-title":"Subclinical AKI is still AKI","volume":"16","author":"Ronco","year":"2012","journal-title":"Crit. Care"},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.109684_bib0085","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ndt\/gfv130","article-title":"Cell-cycle arrest and acute kidney injury: the light and the dark sides","volume":"31","author":"Kellum","year":"2016","journal-title":"Nephrol. Dial. Transplant."},{"issue":"December (3)","key":"10.1016\/j.biopha.2019.109684_bib0090","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1752-8062.2008.00053.x","article-title":"Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans","volume":"1","author":"Vaidya","year":"2008","journal-title":"Clin. Transl. Sci."},{"issue":"November (10)","key":"10.1016\/j.biopha.2019.109684_bib0095","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/ki.2010.267","article-title":"Sub-nephrotoxic doses of gentamicin predispose animals to developing acute kidney injury and to excrete ganglioside M2 activator protein","volume":"78","author":"Quiros","year":"2010","journal-title":"Kidney Int."},{"issue":"February","key":"10.1016\/j.biopha.2019.109684_bib0100","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.tox.2012.12.006","article-title":"Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats","volume":"304","author":"Vicente-Vicente","year":"2013","journal-title":"Toxicology"},{"issue":"April (2)","key":"10.1016\/j.biopha.2019.109684_bib0105","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.toxlet.2014.11.033","article-title":"Sub-nephrotoxic cisplatin sensitizes rats to acute renal failure and increases urinary excretion of fumarylacetoacetase","volume":"234","author":"Vicente-Vicente","year":"2015","journal-title":"Toxicol. Lett."},{"issue":"March (7)","key":"10.1016\/j.biopha.2019.109684_bib0110","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2019.109684_bib0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105988","article-title":"Hypertension and hyperglycemia synergize to cause incipient renal tubular alterations resulting in increased NGAL urinary excretion in rats","volume":"9","author":"Bl\u00e1zquez-Medela","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2019.109684_bib0120","first-page":"391","article-title":"Ueber den Niederschlag welchen Pikrins\u00e4ure in normalen Harn erzeugt und \u00fcber eine neue reaction des Kreatinins","volume":"10","author":"Jaffe","year":"1886","journal-title":"Z Physiol Chem."},{"issue":"July (8)","key":"10.1016\/j.biopha.2019.109684_bib0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/clinchem\/21.8.1136","article-title":"New Colorimetric reaction for end-point, continuous-flow, and kinetic measurement of urea","volume":"21","author":"Jung","year":"1975","journal-title":"Clin. Chem."},{"issue":"May (1)","key":"10.1016\/j.biopha.2019.109684_bib0130","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.biopha.2019.109684_bib0135","doi-asserted-by":"crossref","DOI":"10.3390\/nu8050264","article-title":"Origanum majorana attenuates nephrotoxicity of cisplatin anticancer drug through ameliorating oxidative stress","author":"Soliman","year":"2016","journal-title":"Nutrients [Internet]"},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.109684_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1470-2045(16)30625-8","article-title":"Effects of sodium thiosulfate versus observation on development of cisplatin-induced hearing loss in children with cancer (ACCL0431): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"18","author":"Freyer","year":"2017","journal-title":"Lancet Oncol."},{"issue":"October (10054)","key":"10.1016\/j.biopha.2019.109684_bib0145","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/S0140-6736(16)31388-5","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial","volume":"388","author":"Zhang","year":"2016","journal-title":"Lancet"},{"issue":"57","key":"10.1016\/j.biopha.2019.109684_bib0150","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.niox.2016.04.005","article-title":"Hydrogen sulfide: a novel nephroprotectant against cisplatin-induced renal toxicity","volume":"01","author":"Dugbartey","year":"2016","journal-title":"Nitric Oxide"},{"issue":"March","key":"10.1016\/j.biopha.2019.109684_bib0155","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12885-016-2271-8","article-title":"Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors","volume":"16","author":"Sato","year":"2016","journal-title":"BMC Cancer"},{"issue":"December (12)","key":"10.1016\/j.biopha.2019.109684_bib0160","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00467-014-2935-z","article-title":"Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012","volume":"29","author":"Finkel","year":"2014","journal-title":"Pediatr. Nephrol."},{"issue":"November (10)","key":"10.1016\/j.biopha.2019.109684_bib0165","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3109\/10408444.2011.602662","article-title":"An integrative view of the pathophysiological events leading to cisplatin nephrotoxicity","volume":"41","author":"S\u00e1nchez-Gonz\u00e1lez","year":"2011","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.biopha.2019.109684_bib0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4103\/ijpvm.IJPVM_40_17","article-title":"Prevention of chemotherapy-induced nephrotoxicity in children with cancer","volume":"8","author":"Sharbaf","year":"2017","journal-title":"Int. J. Prev. Med."},{"issue":"February (2)","key":"10.1016\/j.biopha.2019.109684_bib0175","article-title":"Nephrotoxicity as a dose-limiting factor in a high-dose cisplatin-based chemoradiotherapy regimen for head and neck carcinomas","volume":"8","author":"Hoek","year":"2016","journal-title":"Cancers (Basel)"},{"issue":"July","key":"10.1016\/j.biopha.2019.109684_bib0180","doi-asserted-by":"crossref","first-page":"29857","DOI":"10.1038\/srep29857","article-title":"Indole-3-carbinol protects against cisplatin-induced acute nephrotoxicity: role of calcitonin gene-related peptide and insulin-like growth factor-1","volume":"6","author":"El-Naga","year":"2016","journal-title":"Sci. Rep."},{"issue":"April (100)","key":"10.1016\/j.biopha.2019.109684_bib0185","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.ki.5000368","article-title":"Contrast-induced nephropathy: definition, epidemiology, and patients at risk","author":"Mehran","year":"2006","journal-title":"Kidney Int. Suppl."},{"issue":"April (2)","key":"10.1016\/j.biopha.2019.109684_bib0190","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10557-015-6635-0","article-title":"Contrast-induced acute kidney injury: an update","volume":"30","author":"Chalikias","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"May (19)","key":"10.1016\/j.biopha.2019.109684_bib0195","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1161\/01.CIR.0000016043.87291.33","article-title":"Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention","volume":"105","author":"Rihal","year":"2002","journal-title":"Circulation"},{"issue":"May (5)","key":"10.1016\/j.biopha.2019.109684_bib0200","doi-asserted-by":"crossref","first-page":"374","DOI":"10.47102\/annals-acadmedsg.V39N5p374","article-title":"Risk factors and clinical outcomes for contrast-induced nephropathy after percutaneous coronary intervention in patients with normal serum creatinine","volume":"39","author":"Chong","year":"2010","journal-title":"Ann. Acad. Med. Singap."},{"issue":"May (11)","key":"10.1016\/j.biopha.2019.109684_bib0205","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1503\/cmaj.1040847","article-title":"Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies","volume":"172","author":"Goldenberg","year":"2005","journal-title":"CMAJ"},{"issue":"August (3)","key":"10.1016\/j.biopha.2019.109684_bib0210","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jacc.2004.03.080","article-title":"Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial","volume":"44","author":"Nikolsky","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"issue":"May (5)","key":"10.1016\/j.biopha.2019.109684_bib0215","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1053\/ajkd.2002.32766","article-title":"Hospital-acquired renal insufficiency","volume":"39","author":"Nash","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"February (1)","key":"10.1016\/j.biopha.2019.109684_bib0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1091581818819791","article-title":"Investigating the value of urine volume, creatinine, and cystatin C for urinary biomarkers normalization for drug development studies","volume":"38","author":"Adedeji","year":"2019","journal-title":"Int. J. Toxicol."},{"issue":"2","key":"10.1016\/j.biopha.2019.109684_bib0225","first-page":"627","article-title":"Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation","volume":"4","author":"Hajian-Tilaki","year":"2013","journal-title":"Caspian J. Intern. Med."},{"issue":"January (2)","key":"10.1016\/j.biopha.2019.109684_bib0230","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1681\/ASN.2006080908","article-title":"Renal iron metabolism: transferrin iron delivery and the role of Iron regulatory proteins","volume":"18","author":"Zhang","year":"2007","journal-title":"JASN"},{"issue":"May (5)","key":"10.1016\/j.biopha.2019.109684_bib0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1136\/jcp.36.5.539","article-title":"Transferrin receptors in human tissues: their distribution and possible clinical relevance","volume":"36","author":"Gatter","year":"1983","journal-title":"J. Clin. Pathol."},{"issue":"October (22)","key":"10.1016\/j.biopha.2019.109684_bib0240","doi-asserted-by":"crossref","first-page":"12491","DOI":"10.1073\/pnas.211291398","article-title":"Megalin-dependent cubilin-mediated endocytosis is a major pathway for the apical uptake of transferrin in polarized epithelia","volume":"98","author":"Kozyraki","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"February (2)","key":"10.1016\/j.biopha.2019.109684_bib0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1681\/ASN.V132423","article-title":"Megalin and cubilin are endocytic receptors involved in renal clearance of hemoglobin","volume":"13","author":"Gburek","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"issue":"November (11)","key":"10.1016\/j.biopha.2019.109684_bib0250","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1093\/ndt\/gfr525","article-title":"Mouse model of proximal tubule endocytic dysfunction","volume":"26","author":"Weyer","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.109684_bib0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int."},{"issue":"February (2)","key":"10.1016\/j.biopha.2019.109684_bib0260","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/toxsci\/kfq267","article-title":"An integrative overview on the mechanisms underlying the renal tubular cytotoxicity of gentamicin","volume":"119","author":"Quiros","year":"2011","journal-title":"Toxicol. Sci."},{"issue":"October (1)","key":"10.1016\/j.biopha.2019.109684_bib0265","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pharmthera.2012.07.003","article-title":"Subcellular targets of cisplatin cytotoxicity: an integrated view","volume":"136","author":"Sancho-Mart\u00ednez","year":"2012","journal-title":"Pharmacol. Ther."},{"issue":"December (2)","key":"10.1016\/j.biopha.2019.109684_bib0270","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/toxsci\/kfq178","article-title":"Nephrotoxicity of uranium: pathophysiological, diagnostic and therapeutic perspectives","volume":"118","author":"Vicente-Vicente","year":"2010","journal-title":"Toxicol. Sci."},{"issue":"July (1)","key":"10.1016\/j.biopha.2019.109684_bib0275","doi-asserted-by":"crossref","first-page":"F2","DOI":"10.1152\/ajprenal.00072.2007","article-title":"New insights into the pathophysiology of cyclosporine nephrotoxicity: a role of aldosterone","volume":"293","author":"Bobadilla","year":"2007","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"January (1)","key":"10.1016\/j.biopha.2019.109684_bib0280","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4037\/ccn2013680","article-title":"Contrast-induced nephropathy: pathophysiology and preventive strategies","volume":"33","author":"Jorgensen","year":"2013","journal-title":"Crit. Care Nurse"},{"issue":"February (2)","key":"10.1016\/j.biopha.2019.109684_bib0285","first-page":"247","article-title":"Contrast-induced nephropathy: from pathophysiology to preventive strategies","volume":"32","author":"Azzalini","year":"2016","journal-title":"Can. J. Cardiol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219353065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332219353065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:37:01Z","timestamp":1778693821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332219353065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":57,"alternative-id":["S0753332219353065"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109684","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary transferrin pre-emptively identifies the risk of renal damage posed by subclinical tubular alterations","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2019.109684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"109684"}}